Skip to main content
Home
 
 
 
MENU
Home
Janssen’s COVID-19 Vaccine Status >

Janssen Global Main Menu

  • Our Company
    • About Us
    • Contact Us
    • Grants & Giving
    • News Center
    • Our Leaders
    • Patient Safety information
    • Products
    • Sustainability
    • Transparency
    • VISIT JANSSEN IN YOUR COUNTRY
  • Our Focus
    • Therapeutic Areas
    • Cardiovascular, Metabolism and Retina
    • Immunology
    • Infectious Diseases & Vaccines
    • Neuroscience
    • Oncology
    • Pulmonary Hypertension
    • Patient Engagement
  • Our Science
    • Our Response to COVID-19
    • Clinical Trials
    • Compassionate Use & Pre-Approval Access
    • R&D Data Science
    • Janssen Global Trial Finder
    • World Without Disease Accelerator
    • Janssen Clinical Innovation
    • Precision Medicine & Janssen Diagnostics

Our Stories List

Making a Splash for Disease Awareness
Global_Trial_Finder
Making a Splash for Disease Awareness
Looking Under the Hood for Green Chemistry Solutions
Global_Trial_Finder
Looking Under the Hood for Green Chemistry Solutions
  • Return to home

Global Trial Finder

  • text size

My Saved Trials

A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

Last Updated   May 7, 2025

Want to learn how to participate in this trial?

CR109137

OVERVIEW

  • Sexes Eligible for Study
    all
  • Age
    2+ years
  • Phase
    phase 2
    2
  • Sites
    19 Sites
  • Status
    Recruiting

SUMMARY

The purpose of this study is to determine the effect of nipocalimab on total serum immunoglobulin G (IgG) in pediatric participants 2 to less than (<) 18 years of age (globally) and 8 to <18 years of age (for Unites Stated (US) sites only), the safety and tolerability of treatment with nipocalimab in children and adolescents and to evaluate the pharmacokinetics (PK) of nipocalimab in children and adolescents with generalized myasthenia gravis (gMG) who have an insufficient clinical response to ongoing, stable standard-of-care therapy.

CONDITIONS

  • Myasthenia Gravis

ELIGIBILITY


Key Inclusion Criteria:

* Age: For US sites only: 8 to <18 years
* Diagnosis of myasthenia gravis (MG) with generalized muscle weakness meeting the clinical criteria for generalized myasthenia gravis (gMG) as defined by the Myasthenia Gravis Foundation of America (MGFA) Clinical Classification Class IIa/b, IIIa/b, or IVa/b at screening
* Has a positive serologic test for acetylcholine receptor (anti-AChR) antibodies or muscle-specific tyrosine kinase (anti-MuSK) antibodies at screening
* A participant using herbal, naturopathic, traditional Chinese remedies, ayurvedic or nutritional supplements, or medical marijuana (with a doctor's prescription) is eligible if the use of these medications is acceptable to the Investigator. These remedies must remain at a stable dose and regimen throughout the study
* Has sufficient venous access to allow drug administration by infusion and blood sampling as per the protocol
* Participants should have a body weight and body mass index between 5th and 95th percentile for age and sex. Obese participants greater than 95th percentile and underweight participants below 5th percentile may participate following medical clearance
* A female of childbearing potential must have a negative highly sensitive serum (beta-human chorionic gonadotropin [beta-hCG]) at Screening and a negative urine pregnancy test at Day 1 prior to administration of study intervention


Key Exclusion Criteria:

* Has a history of severe and/or uncontrolled hepatic (example, viral/alcoholic/ autoimmune hepatitis/ cirrhosis/ and/or metabolic liver disease), gastrointestinal, renal, pulmonary, cardiovascular (including congenital heart diseases), psychiatric, neurological musculoskeletal disorder, any other medical disorder(s) (example, diabetes mellitus), or clinically significant abnormalities in screening laboratory, that might interfere with participant's full participation in the study, and/ or might jeopardize the safety of the participant or the validity of the study results
* Has any confirmed or suspected clinical immunodeficiency syndrome not related to treatment of his/her generalized myasthenia gravis (gMG), or has a family history of congenital or hereditary immunodeficiency unless confirmed absent in the participant
* Has had a thymectomy within 12 months prior to screening, or thymectomy is planned during the Active treatment Phase of the study
* Has shown a previous severe immediate hypersensitivity reaction, such as anaphylaxis to therapeutic proteins (example, monoclonal antibodies)
* Has experienced myocardial infarction, unstable ischemic heart disease, or stroke within 12 weeks of screening


Key Inclusion Criteria:

* Age: For US sites only: 8 to <18 years
* Diagnosis of myasthenia gravis (MG) with generalized muscle weakness meeting the clinical criteria for generalized myasthenia gravis (gMG) as defined by the Myasthenia Gravis Foundation of America (MGFA) Clinical

More...

DETAILS

LOCATIONS

Locations in:
United States, Japan, Netherlands, Poland
Country (4) City or Province (19) Status
United States Phoenix Phoenix Children's Hospital
RECRUITING
United States Los Angeles Childrens Hospital Los Angeles
RECRUITING
United States Palo Alto Lucile Packard Children's Hospital Stanford
RECRUITING
United States San Francisco UCSF Benioff Children's Hospital
RECRUITING
United States Aurora Children's Hospital Colorado
RECRUITING
United States Tampa University of South Florida Morsani Center for Advanced Healthcare
RECRUITING
United States Lawrence University of Kansas Medical Center
RECRUITING
United States Ann Arbor C.S. Mott Children's Hospital
RECRUITING
United States Philadelphia Childrens Hospital Of Philadelphia
RECRUITING
United States Pittsburgh University of Pittsburgh Medical Center
TERMINATED
Japan Chiba Chiba University Hospital
RECRUITING
Japan Miyazaki University of Miyazaki Hospital
RECRUITING
Japan Nishinomiya-Shi Hyogo College of Medicine Hospital
RECRUITING
Japan Saitama shi Saitama Prefecture Children's Medical Center
RECRUITING
Japan Shinjuku-ku Tokyo Women's Medical University Hospital
RECRUITING
Netherlands Leiden Leiden University Medical Center
RECRUITING
United States Hershey Penn State Milton S Hershey Medical Ctr
RECRUITING
Japan Azumino-shi Nagano Children's Hospital
RECRUITING
Poland Gdansk Uniwersyteckie Centrum Kliniczne
RECRUITING
Show More
Geo Locations

33.44838, -112.07404

34.05223, -118.24368

37.44188, -122.14302

37.77493, -122.41942

39.72943, -104.83192

27.94752, -82.45843

38.97167, -95.23525

42.27756, -83.74088

39.95233, -75.16379

40.44062, -79.99589

35.6, 140.11667

31.91667, 131.41667

34.71562, 135.33199

35.90807, 139.65657

35.2946, 139.57059

52.15833, 4.49306

40.28592, -76.65025

36.28815, 137.88705

54.35205, 18.64637

x
50

Indicates 50+ sites in this region: click to zoom in.

10

Indicates 10+ sites in this region: click to zoom in.

5

Indicates < 10 sites in this region: click to zoom in.

Corresponds to individual site.

Interested in participating?

×

Confirm


If you are interested in this clinical trial, we will use your email address to respond to your questions and fulfill your requests as necessary for our legitimate interest and possibly to comply with our legal obligations relating to pharmacovigilance. Please read our Privacy Policy.

Footer

  • PRIVACY POLICY
  • LEGAL NOTICE
  • COOKIE POLICY
  • COOKIE SETTINGS
  • CAREERS
  • NEWS CENTER
  • DO NOT SELL MY PERSONAL INFORMATION

Footer Social

Find Janssen Global on:

twitter youtube linkedin

Janssen Global Policy text

©Johnson & Johnson Innovative Medicine. All Rights Reserved. This website is hosted and operated by Johnson & Johnson Innovative Medicine, which is solely responsible for its content. This website is intended for a global audience.